Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.

Abstract: Provided are a dynamically self-balancing pressurized borehole sealing apparatus and a method thereof for coal seam gas pressure measurement, wherein the dynamically self-balancing pressurized borehole sealing apparatus for coal seam gas pressure measurement comprises a pressure measuring tube arranged in a borehole, one end of the pressure measuring tube is provided with a pressure measuring unit for measuring a gas pressure, the pressure measuring tube is surrounded and wrapped with an expansion airbag, the pressure measuring tube is provided with a pressure introducing hole communicating with the expansion airbag, both sides of the expansion airbag on the pressure measuring tube are surrounded and wrapped with a front borehole sealing airbag and a rear borehole sealing airbag respectively, a gel injection chamber is reserved between the three of the front borehole sealing airbag, the rear borehole sealing airbag and the expansion airbag and an inner side of the borehole, the gel injection chamber is filled

Abstract: Embodiments of the present disclosure are directed toward a falling-film evaporator that includes an evaporator cylinder, a mist eliminator disposed in the evaporator cylinder, a dispenser disposed in the evaporator cylinder, a liquid baffle disposed in the evaporator cylinder, a first chamber formed at least partially by the mist eliminator and the liquid baffle on a first side of the evaporator cylinder below the mist eliminator, a gas returning chamber formed at least partially by the mist eliminator and the liquid baffle on a second side of the evaporator cylinder above the mist eliminator, a gas-liquid separation chamber formed at least partially by the dispenser at an upper portion of the first chamber, and an evaporation chamber formed at least partially by the dispenser at a lower portion of the first chamber, and where the gas returning chamber is in fluid communication with the evaporation chamber.

Abstract: The present disclosure relates to an oil flow switch, comprising a float device connected to a circulating oil passage and a floating liquid level switch element provided in the float device, wherein the float device comprises an oil inlet, an oil outlet, and a float chamber provided between the oil inlet and the oil outlet, the floating liquid level switch element is provided in the float chamber, and the float device is provided with a channel in communication with the float chamber. The oil flow switch according to the present disclosure may avoid a false alarm of the oil level switch and meanwhile mitigate disturbance to the float caused by liquid level fluctuation to reduce friction between the float and the sleeve rod.

Abstract: A falling-film evaporator includes an evaporator cylinder, a mist eliminator disposed in the evaporator cylinder, a dispenser disposed in the evaporator cylinder, a liquid baffle disposed in the evaporator cylinder, a first chamber formed at least partially by the mist eliminator and the liquid baffle on a first side of the evaporator cylinder below the mist eliminator, a gas returning chamber formed at least partially by the mist eliminator and the liquid baffle on a second side of the evaporator cylinder above the mist eliminator, a gas-liquid separation chamber formed at least partially by the dispenser at an upper portion of the first chamber, and an evaporation chamber formed at least partially by the dispenser at a lower portion of the first chamber, and where the gas returning chamber is in fluid communication with the evaporation chamber.

Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.

Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.

Abstract: Embodiments of the present disclosure are directed toward a falling-film evaporator that includes an evaporator cylinder, a mist eliminator disposed in the evaporator cylinder, a dispenser disposed in the evaporator cylinder, a liquid baffle disposed in the evaporator cylinder, a first chamber formed at least partially by the mist eliminator and the liquid baffle on a first side of the evaporator cylinder below the mist eliminator, a gas returning chamber formed at least partially by the mist eliminator and the liquid baffle on a second side of the evaporator cylinder above the mist eliminator, a gas-liquid separation chamber formed at least partially by the dispenser at an upper portion of the first chamber, and an evaporation chamber formed at least partially by the dispenser at a lower portion of the first chamber, and where the gas returning chamber is in fluid communication with the evaporation chamber.

Abstract: An electronic device, and a power supplying method and a wireless power supplying system thereof. The electronic device includes a wired electric power receiving module, a wireless electric power receiving module and a switch. The wired electric power receiving module is connected to an external power supply by wired transmission. The wireless electric power receiving module receives the wireless electric power from an external wireless electric power transmitting device. The switch is coupled to the wired electric power receiving module and the wireless electric power receiving module and is used to switch between the wired electric power receiving module and the wireless electric power receiving module, to supply the operating voltage. The electronic device can operate in the wireless power supplying mode or the wired power supplying mode, so as to facilitate a user to use.

Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.

Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.

Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.

Abstract: The present invention provides a process for preparing pemetrexed disodium and its intermediate, 4-(4-carbomethoxyphenyl)butanal. The process for preparing the intermediate comprises the following steps: condensing methyl 4-bromobenzoate with 3-buten-1-ol; extracting with an organic solvent during the work-up; adding silica gel to decolorize; and evaporating the organic solvent to give 4-(4-carbomethoxyphenyl)butanal. The product obtained by the present process, with a yield of higher than 80%, and a purity measured by GC of higher than 95%, may be directly used in the next bromination reaction for synthesizing pemetrexed disodium without purification. The present process is suitable for industrial production, as the operation is simple and the reagents used are cheap and readily available.

Abstract: An electronic device, and a power supplying method and a wireless power supplying system thereof. The electronic device includes a wired electric power receiving module, a wireless electric power receiving module and a switch. The wired electric power receiving module is connected to an external power supply by wired transmission. The wireless electric power receiving module receives the wireless electric power from an external wireless electric power transmitting device. The switch is coupled to the wired electric power receiving module and the wireless electric power receiving module and is used to switch between the wired electric power receiving module and the wireless electric power receiving module, to supply the operating voltage. The electronic device can operate in the wireless power supplying mode or the wired power supplying mode, so as to facilitate a user to use.

Abstract: The present invention discloses a process for stereoselective synthesis of Lamivudine comprising the following steps: (a) performing a glycosylation reaction between the compound of formula (I) and cytosine or protected cytosine, and separating the reaction product by recrystallization to obtain the intermediate of formula (II); and (b) deprotecting the intermediate of formula (II) to obtain Lamivudine.

Abstract: The present invention provides a process for preparing pemetrexed disodium and its intermediate, 4-(4-carbomethoxyphenyl)butanal. The process for preparing the intermediate comprises the following steps: condensing methyl 4-bromobenzoate with 3-buten-1-ol; extracting with an organic solvent during the work-up; adding silica gel to decolorize; and evaporating the organic solvent to give 4-(4-carbomethoxyphenyl)butanal. The product obtained by the present process, with a yield of higher than 80%, and a purity measured by GC of higher than 95%, may be directly used in the next bromination reaction for synthesizing pemetrexed disodium without purification. The present process is suitable for industrial production, as the operation is simple and the reagents used are cheap and readily available.

Abstract: The present invention discloses a process for stereoselective synthesis of Lamivudine comprising the following steps: (a) performing a glycosylation-reaction between the compound of formula (I) and cytosine or protected cytosine, and separating the reaction product by recrystallization to obtain the intermediate of formula (II); and (b) deprotecting the intermediate of formula (II) to obtain Lamivudine.

Abstract: The present invention discloses a process for stereoselective synthesis of Lamivudine comprising the following steps: (a) performing a glycosylation-reaction between the compound of formula (I) and cytosine or protected cytosine, and separating the reaction product by recrystallization to obtain the intermediate of formula (II); and (b) deprotecting the intermediate of formula (II) to obtain Lamivudine.

Abstract: A process for stereoselective synthesis of lamivudine, comprising (a) glycosylation of compounds of formula (I) and cytosine or protected cytosine, separating the resulting products by crystallization to afford intermediates of formula (II); (b) removing the protecting groups of intermediates of formula (II) to obtain lamivudine.

Abstract: A method to prepare Docetaxel trihydrate using the mixture of acetone and water, which provides the product with good stability, less experiment time, less exposal to light, and avoids purity decreasing. The process is simple and easy to operate.